3B BlackBio Dx Ltd

As of June 30, 2026, 3B BlackBio Dx Ltd carries a market capitalization of 10.00B, placing it among publicly traded companies globally. Its enterprise value stands at 10.00B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

3B BlackBio Dx Ltd's next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, 3B BlackBio Dx Ltd has 8.58M shares outstanding.

As of June 30, 2026, 3B BlackBio Dx Ltd trades at a trailing price-to-earnings ratio of 17.79.

As of June 30, 2026, 3B BlackBio Dx Ltd trades at an EV/EBITDA multiple of 18.84 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 6.53 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 21.33 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 10.00B versus a market cap of 10.00B, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 17.92M in revenue per employee across its workforce of 85.50, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, 3B BlackBio Dx Ltd recorded 180.62M in income tax expense. That works out to an effective tax rate of 24.30, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 743.26M, leaving 555.29M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, 3B BlackBio Dx Ltd's stock has declined approximately 4.00% over the past 52 weeks. The 50-day moving average sits at 1,408.47, while the 200-day moving average is 1,347.00.

Over the twelve months ended June 30, 2026, 3B BlackBio Dx Ltd generated 1.53B in revenue and converted that into 555.29M in net income, yielding earnings per share of 66.39. EBITDA reached 530.92M, while operating income came in at 468.99M.

Over the twelve months ended June 30, 2026, 3B BlackBio Dx Ltd posted a gross margin of 75.05, reflecting its pricing power and cost economics. The operating margin of 30.62 and net profit margin of 36.25 provide insight into operational efficiency.